Machine-Learning and Chemicogenomics Approach Defines and Predicts Cross-Talk of Hippo and MAPK Pathways.

Journal: Cancer discovery
PMID:

Abstract

Hippo pathway dysregulation occurs in multiple cancers through genetic and nongenetic alterations, resulting in translocation of YAP to the nucleus and activation of the TEAD family of transcription factors. Unlike other oncogenic pathways such as RAS, defining tumors that are Hippo pathway-dependent is far more complex due to the lack of hotspot genetic alterations. Here, we developed a machine-learning framework to identify a robust, cancer type-agnostic gene expression signature to quantitate Hippo pathway activity and cross-talk as well as predict YAP/TEAD dependency across cancers. Further, through chemical genetic interaction screens and multiomics analyses, we discover a direct interaction between MAPK signaling and TEAD stability such that knockdown of YAP combined with MEK inhibition results in robust inhibition of tumor cell growth in Hippo dysregulated tumors. This multifaceted approach underscores how computational models combined with experimental studies can inform precision medicine approaches including predictive diagnostics and combination strategies. SIGNIFICANCE: An integrated chemicogenomics strategy was developed to identify a lineage-independent signature for the Hippo pathway in cancers. Evaluating transcriptional profiles using a machine-learning method led to identification of a relationship between YAP/TAZ dependency and MAPK pathway activity. The results help to nominate potential combination therapies with Hippo pathway inhibition..

Authors

  • Trang H Pham
    Department of Discovery Oncology, Genentech, Inc., South San Francisco, California.
  • Thijs J Hagenbeek
    Department of Discovery Oncology, Genentech, Inc., South San Francisco, California.
  • Ho-June Lee
    Department of Discovery Oncology, Genentech, Inc., South San Francisco, California.
  • Jason Li
    Department of Bioinformatics, Genentech, Inc., South San Francisco, California.
  • Christopher M Rose
    Department of Microchemistry, Proteomics, and Lipidomics, Genentech, Inc., South San Francisco, California.
  • Eva Lin
    Department of Discovery Oncology, Genentech, Inc., South San Francisco, California.
  • Mamie Yu
    Department of Discovery Oncology, Genentech, Inc., South San Francisco, California.
  • Scott E Martin
    Department of Discovery Oncology, Genentech, Inc., South San Francisco, California.
  • Robert Piskol
    Department of Bioinformatics, Genentech, Inc., South San Francisco, California.
  • Jennifer A Lacap
    Department of Translational Oncology, Genentech, Inc., South San Francisco, California.
  • Deepak Sampath
    Department of Translational Oncology, Genentech, Inc., South San Francisco, California.
  • Victoria C Pham
    Department of Microchemistry, Proteomics, and Lipidomics, Genentech, Inc., South San Francisco, California.
  • Zora Modrusan
    Department of Molecular Biology, Genentech, Inc., South San Francisco, California.
  • Jennie R Lill
    Genentech, South San Francisco, CA, United States.
  • Christiaan Klijn
    Department of Bioinformatics, Genentech, Inc., South San Francisco, California.
  • Shiva Malek
    Department of Discovery Oncology, Genentech, Inc., South San Francisco, California.
  • Matthew T Chang
    Department of Bioinformatics, Genentech, Inc., South San Francisco, California. anweshad@gene.com matthew.chang1@gmail.com.
  • Anwesha Dey
    Department of Discovery Oncology, Genentech, Inc., South San Francisco, California. anweshad@gene.com matthew.chang1@gmail.com.